141 related articles for article (PubMed ID: 33846854)
1. A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.
Onaka T; Kato-Ogura A; Otsuka Y; Iwai F; Yonezawa A
Ann Hematol; 2022 Feb; 101(2):457-458. PubMed ID: 33846854
[No Abstract] [Full Text] [Related]
2. Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.
Oncologist; 2021 Feb; 26 Suppl 1(Suppl 1):S10. PubMed ID: 33368797
[TBL] [Abstract][Full Text] [Related]
3. Gilteritinib Changes AML Landscape.
Saleh N
Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469903
[No Abstract] [Full Text] [Related]
4. Gilteritinib induces differentiation in relapsed and refractory
McMahon CM; Canaani J; Rea B; Sargent RL; Qualtieri JN; Watt CD; Morrissette JJD; Carroll M; Perl AE
Blood Adv; 2019 May; 3(10):1581-1585. PubMed ID: 31122910
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with gilteritinib for initially FMS-like tyrosine kinase 3 gene internal tandem duplications-positive elderly refractory acute myeloid leukemia that changed into FMS-like tyrosine kinase 3 gene tyrosine kinase domain-positive after cord blood transplantation.
Akahane D; Moriyama M; Yoshizawa S; Katagiri S; Fujimoto H; Gotoh A
Geriatr Gerontol Int; 2019 Oct; 19(10):1063-1064. PubMed ID: 31602758
[No Abstract] [Full Text] [Related]
6. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
Usuki K; Sakura T; Kobayashi Y; Miyamoto T; Iida H; Morita S; Bahceci E; Kaneko M; Kusano M; Yamada S; Takeshita S; Miyawaki S; Naoe T
Cancer Sci; 2018 Oct; 109(10):3235-3244. PubMed ID: 30039554
[TBL] [Abstract][Full Text] [Related]
7. Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.
Zeidan AM; Qi CZ; Yang H; Garnham A; Shah MV; Pandya BJ
Leuk Lymphoma; 2022 Mar; 63(3):762-764. PubMed ID: 34749571
[No Abstract] [Full Text] [Related]
8. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
[TBL] [Abstract][Full Text] [Related]
9. Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a
Ballesta-López O; Solana-Altabella A; Megías-Vericat JE; Martínez-Cuadrón D; Montesinos P
Future Oncol; 2021 Jan; 17(2):215-227. PubMed ID: 32975130
[TBL] [Abstract][Full Text] [Related]
10. Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report.
Abematsu T; Nishikawa T; Shiba N; Iijima-Yamashita Y; Inaba Y; Takahashi Y; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
Pediatr Blood Cancer; 2021 Nov; 68(11):e29216. PubMed ID: 34245496
[No Abstract] [Full Text] [Related]
11. Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib.
Tasaka K; Kato I; Takeshita S; Yoshioka Y; Usami A; Uchihara Y; Akazawa R; Kamitori T; Saida S; Umeda K; Hiramatsu H; Adachi S; Takita J
Pediatr Blood Cancer; 2023 May; 70(5):e30185. PubMed ID: 36579805
[No Abstract] [Full Text] [Related]
12. A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.
Perrone S; Ortu La Barbera E; Viola F; Cipollone E; Scerpa MC; Siniscalchi R; Ottone T; Voso MT; Cimino G
Chemotherapy; 2021; 66(4):134-138. PubMed ID: 34515081
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
14. [Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation].
Miyajima T; Harada S; Ogasawara R; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Chi S; Minami Y; Kondo T
Rinsho Ketsueki; 2022; 63(1):51-54. PubMed ID: 35135952
[TBL] [Abstract][Full Text] [Related]
15. A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
Joshi SK; Sharzehi S; Pittsenbarger J; Bottomly D; Tognon CE; McWeeney SK; Druker BJ; Traer E
Am J Hematol; 2021 Jul; 96(7):E226-E229. PubMed ID: 33780043
[No Abstract] [Full Text] [Related]
16. Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of
Kondo T; Onozawa M; Fujisawa S; Harada S; Ogasawara R; Izumiyama K; Saito M; Morioka M; Mori A; Teshima T
Hematology; 2021 Dec; 26(1):256-260. PubMed ID: 33631087
[No Abstract] [Full Text] [Related]
17. Closing in on targeted therapy for acute myeloid leukaemia.
The Lancet Haematology
Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
[No Abstract] [Full Text] [Related]
18. An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor.
Kim RS; Yaghy A; Wilde LR; Shields CL
JAMA Ophthalmol; 2020 Apr; 138(4):418-419. PubMed ID: 32163103
[No Abstract] [Full Text] [Related]
19. Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia
Vignal N; Kelly L; Lengline E; Cabannes-Hamy A; Siavellis J; Ghez D; Sauvageon H; Braun T; Jacqz-Aigrain E; Kohn M; Rousselot P; Puissant A; Raffoux E; Mourah S; Goldwirt L
Haematologica; 2023 Sep; 108(9):2531-2534. PubMed ID: 36794507
[No Abstract] [Full Text] [Related]
20. Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.
Reed DR; Sen JM; Pierce EJ; Elsarrag RZ; K Keng M
J Oncol Pharm Pract; 2020 Jul; 26(5):1200-1212. PubMed ID: 32338136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]